Markets

AbbVie And Valkai Collaborate To Accelerate Pace Of Scientific Innovation's Reach To Patients

Sep 29, 2026 · 09:08 AM ET· updated 1h ago

AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation

Why It Matters

AbbVie is partnering with an AI company to help get new medicines to patients faster. When a medicine company invests in new tools, watch if they actually launch better products sooner.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABBV262.11

-4.17 (-1.57%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.